세계의 심장 이식 치료 시장 - 규모, 점유율, 동향 분석 보고서 : 약제 유형별, 유통 채널별, 지역별, 부문 예측(2024-2030년)

Market Size & Trends

The global heart transplantation therapeutics market size was estimated at USD 1.08 billion in 2023 and is anticipated to grow at a CAGR of 4.25% from 2024 to 2030. The rising incidence of cardiovascular diseases (CVDs), such as heart failure, coronary artery disease, and cardiomyopathy, majorly drives this growth. For instance, according to the PCR online, CVD continues to be the primary cause of death for both men and women worldwide. As of 2023, the global population is 8 billion, with approximately 620 million individuals living with heart and circulatory diseases. Each year, approximately 60 million people worldwide develop heart or circulatory diseases.

Furthermore, the increasing prevalence of hypertrophic cardiomyopathy (HCM)is one of the major factors contributing to the growth of the market for heart transplantation therapeutics. It is considered the most common inherited cardiomyopathy worldwide. As per the Cleveland Clinic[, the prevalence of HCM is estimated to affect approximately 1 in 500 individuals worldwide. This condition can lead to various complications, including arrhythmias, heart failure, and sudden cardiac death.Apart from hypertrophic cardiomyopathy, other genetic types of cardiomyopathies impact the market growth effectively. These include dilated cardiomyopathy, restrictive cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy. Dilated cardiomyopathy is more prevalent than HCM, affecting about 1 in 2,000 to 2,500 individuals.

The growing efforts to raise awareness about organ donation and transplantation have led to more individuals consenting to donate their organs after death. For instance, in May 2023, the Minister for Health, Stephen Donnelly, launched Organ Donor Awareness Week 2023, focusing on the progress made in organ donation and transplantation services in Ireland. In his speech, he highlighted the system's recovery from the impact of COVID-19, with 250 transplants performed in the previous year and a remarkable start to 2023 with 81 transplants in the first quarter. The Minister expressed gratitude to all involved in the process, including transplant centers, ICU staff, organ donor nurse managers, and Organ Donation and Transplant Ireland. This has helped alleviate the shortage of donor hearts available for transplantation, thereby supporting the growth of the heart transplantation therapeutics market.

Moreover, the rising geriatric population worldwide is a common factor but significantly boosts market growth. The prevalence of age-related cardiovascular conditions that may necessitate heart transplantation is on the rise. Older individuals are more likely to develop heart failure or other cardiac issues that could benefit from heart transplant therapy, thereby driving the market growth.According to the National Center for Health Statistics, in 2020, 6.3% of adults aged 18 years and over had been diagnosed with heart disease in the U.S. This estimate is based on household interviews of a sample of the civilian, noninstitutionalized U.S. population.

In 2023, findings from the Institute for Health Metrics and Evaluation study on the global burden of cardiovascular diseases and risks for 1990-2022 revealed significant insights.

• Age-standardized cardiovascular disease (CVD) mortality rates varied regionally, ranging from 73.6 per 100,000 in High-income Asia Pacific to 432.3 per 100,000 in Eastern Europe in 2022.
• Global CVD mortality significantly decreased by 34.9% from 1990 to 2022.
• Leading Causes of Disability-Adjusted Life Years (DALYs): ischemic heart disease emerged as the leading global cause with age-standardized DALYs at 2,275.9 per 100,000. Intracerebral hemorrhage and ischemic stroke followed closely as prominent CVD causes for age-standardized DALYs.
• Age-standardized CVD Prevalence: Varied globally, with rates ranging from 5,881.0 per 100,000 in South Asia to 11,342.6 per 100,000 in Central Asia.
• Leading Risk Factor: High systolic blood pressure accounted for the largest number of attributable age-standardized CVD DALYs at 2,564.9 per 100,000 globally.
• Significant Changes in Risk Factors (1990 to 2022): Household air pollution from solid fuels experienced the most substantial change, with a 65.1% decrease in attributable age-standardized DALYs.

Government initiatives aimed at improving organ donation rates, funding research in transplant medicine, and streamlining regulatory processes for organ transplantation have also played a role in driving the heart transplantation therapeutics market forward. These supportive measures create a conducive environment for advancements in this field.In January 2024, the International Society for Heart and Lung Transplantation (ISHLT) disclosed that it has allocated over USD 400,000 in funding to support research endeavors. It aims to enhance the care of patients with advanced heart and lung diseases. These grants were made possible through the financial backing of the ISHLT Foundation. Notably, these grants represent the second round of funding for the 2023 ISHLT grant cycles.

Global Heart Transplantation Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global heart transplantation therapeutics market report based on drug type, distribution channel, and region:

• Drug Type Outlook (Revenue, USD Million, 2018 - 2030￢)
• Immunosuppressants
• Anti-infectives
• Analgesics
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Region Outlook (Revenue, USD Million, 2018 - 2030)
• North America

U.S.

Canada

Mexico

• Europe

UK

Germany

France

Italy

Spain

Norway

Sweden

Denmark

• Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

• Latin America

Brazil

Argentina

• Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.1. Segment Definitions
  • 1.1.1. Drug Type
  • 1.1.2. Distribution Channel
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecasts timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
    • 1.3.5.1. Data for primary interviews in North America
    • 1.3.5.2. Data for primary interviews in Europe
    • 1.3.5.3. Data for primary interviews in Asia Pacific
    • 1.3.5.4. Data for primary interviews in Latin America
    • 1.3.5.5. Data for Primary interviews in MEA
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
  • 1.6.3. Volume price analysis (Model 2)
  • 1.6.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug type outlook
  • 2.2.2. Distribution channel outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Heart Transplantation Therapeutics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Heart Transplantation Therapeutics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Heart Transplantation Therapeutics Market: Drug Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Heart Transplantation Therapeutics Market: Drug Type Movement Analysis
• 4.3. Heart Transplantation Therapeutics Market by Drug Type Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Immunosuppressants
  • 4.5.1. Immunosuppressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Anti-infectives
  • 4.6.1. Anti-infectives Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Analgesics
  • 4.7.1. Analgesics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Heart Transplantation Therapeutics Market: Distribution Channel Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Heart Transplantation Therapeutics Market: Distribution Channel Movement Analysis
• 5.3. Heart Transplantation Therapeutics Market by Distribution Channel Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Hospital Pharmacies
  • 5.5.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Retail Pharmacies
  • 5.6.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Online pharmacies
  • 5.7.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Heart Transplantation Therapeutics Market: Regional Estimates & Trend Analysis

• 6.1. Regional Dashboard
• 6.2. Regional Heart Transplantation Therapeutics Market Movement Analysis
• 6.3. Heart Transplantation Therapeutics Market: Regional Estimates & Trend Analysis by Technology & End use
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. North America
  • 6.5.1. North America Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. U.S.
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement scenario
    • 6.5.2.5. U.S. Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Canada
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement scenario
    • 6.5.3.5. Canada Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. Mexico
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Competitive Scenario
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement scenario
    • 6.5.4.5. Mexico Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Europe
  • 6.5.6. Europe Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. UK
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Competitive Scenario
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement scenario
    • 6.5.7.5. UK Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Germany
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Competitive Scenario
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement scenario
    • 6.5.8.5. Germany Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. France
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Competitive Scenario
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement scenario
    • 6.5.9.5. France Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.10. Italy
    • 6.5.10.1. Key Country Dynamics
    • 6.5.10.2. Competitive Scenario
    • 6.5.10.3. Regulatory Framework
    • 6.5.10.4. Reimbursement scenario
    • 6.5.10.5. Italy Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.11. Spain
    • 6.5.11.1. Key Country Dynamics
    • 6.5.11.2. Competitive Scenario
    • 6.5.11.3. Regulatory Framework
    • 6.5.11.4. Reimbursement scenario
    • 6.5.11.5. Spain Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.12. Denmark
    • 6.5.12.1. Key Country Dynamics
    • 6.5.12.2. Competitive Scenario
    • 6.5.12.3. Regulatory Framework
    • 6.5.12.4. Reimbursement scenario
    • 6.5.12.5. Denmark Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.13. Sweden
    • 6.5.13.1. Key Country Dynamics
    • 6.5.13.2. Competitive Scenario
    • 6.5.13.3. Regulatory Framework
    • 6.5.13.4. Reimbursement scenario
    • 6.5.13.5. Sweden Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.14. Norway
    • 6.5.14.1. Key Country Dynamics
    • 6.5.14.2. Competitive Scenario
    • 6.5.14.3. Regulatory Framework
    • 6.5.14.4. Reimbursement scenario
    • 6.5.14.5. Norway Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement scenario
    • 6.6.2.5. Japan Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement scenario
    • 6.6.3.5. China Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Competitive Scenario
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement scenario
    • 6.6.4.5. India Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Competitive Scenario
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement scenario
    • 6.6.5.5. South Korea Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Competitive Scenario
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement scenario
    • 6.6.6.5. Australia Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Competitive Scenario
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement scenario
    • 6.6.7.5. Thailand Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement scenario
    • 6.7.2.5. Brazil Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement scenario
    • 6.7.3.5. Argentina Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Middle East & Africa
  • 6.8.1. Middle East & Africa Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Competitive Scenario
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement scenario
    • 6.8.2.5. South Africa Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Competitive Scenario
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement scenario
    • 6.8.3.5. Saudi Arabia Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Competitive Scenario
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement scenario
    • 6.8.4.5. UAE Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Competitive Scenario
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement scenario
    • 6.8.5.5. Kuwait Heart Transplantation Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Key Company Profiles
  • 7.2.1. Astellas Pharma Inc.
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. Biocon Ltd.
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Dr Reddys Laboratories Ltd.
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Endo International Plc
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. GlaxoSmithKline Plc
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Glenmark Pharmaceuticals Ltd.
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Intas Pharmaceuticals Ltd.
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. Jubilant Pharmova Ltd.
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. LEO Pharma AS
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. Lupin Ltd.
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives